CellMiner address:	http://discover.nci.nih.gov/cellminer/			William C. Reinhold				
										NIH				
										Developmental Therapeutics Branch				
										Phone	301-496-9572			
										FAX	301-402-0752			
										wcr@mail.nih.gov				
Table 1: Metadata on the NCI-60 panel of cancer cell lines														
Cell Line Name	tissue of origin (a)	age (a)	sex (a)	prior treatment (a,b)	Epithelial	histology (a,c)	source	ploidy (d)	p53 (e)	mdr (f)	doubling time (g)	Institute 	Contributor	Reference
BR:MCF7	Breast	69	F	NA	yes	Adenocarcinoma- mammary gland; breast; metastatic site: pleural effusion;	Pleural effusion	3n-, Hypotriploid (58-68)	WT	14	25.4	Michigan Cancer Foundtion	C.M. McGrath	JNCI 51: 1409-1417,1973
BR:MDA_MB_231	Breast	51	F	NA	yes	Adenocarcinoma-mammary gland; breast; epithelial; metastatic site: pleural effusion;	Pleural effusion	2n+, Hyperdiploid (47-57)	MT	29	41.9	MD Anderson Hospital and Tumor Institute	R. Cailleau	JNCI 53(3): 661-674,1974
BR:HS578T	Breast	74	F	NA	yes	Carcinosarcoma-mammary gland; breast	Primary	2n+, Hyperdiploid (47-57)	MT	NA	53.8	Naval Bioscience Laboratory	A.J. Hackett	JNCI 58: 1795-1806,1977
BR:BT_549	Breast	72	F	NA	yes	Papillary infiltrating ductal carcinoma-mammary gland; breast	Metastasis	3n+/-, Near-triploid 69+/- (58-80)	?	-45	53.9	?	W. Coutinho; E.Y. Lasfargues	no pub
BR:T47D	Breast	54	F	NA	yes	infiltrating ductal carcinoma	NA	2n+, Hyperdiploid (47-57)	MT	19	45.5	?	I. Keydar	Eur J Cancer 15:659-679,1979
CNS:SF_268	Central nervous system	24	F	Rad	no	Glioblastoma, ud	NA	2n+, Hyperdiploid (47-57)	MT	-38	33.1	?	P.L.Kornblith	Acta Neuropathol 75: 92-103, 1987
CNS:SF_295	Central nervous system	67	F	Rad	no	Glioblastoma, ud	NA	5n+/-, Near-pentaploid 115+/- (104-126)	MT	91	29.5	University of California	M.L. Rosenblum	Acta Neuropathol 75: 92-103, 1988
CNS:SF_539	Central nervous system	34	F	Rad/BCNU/5FU/HU/6MP	no	Glial cell neoplasm	NA	4n+/-, Near-tetraploid 92+/- (81-103)	WT	-40	35.4	University of California	M.L. Rosenblum	J Neuropathol Exp Neurol 40: 201-229, 1981
CNS:SNB_19	Central nervous system	47	M	None	no	Glioblastoma, ud	NA	3n+/-, Near-triploid 69+/- (58-80)	MT	-41	34.6	NINCDS	P.L. Kornblith	Cancer 47: 255, 1981
CNS:SNB_75	Central nervous system	NA	F	None	no	Astrocytoma	NA	2n+, Hyperdiploid (47-57)	MT	-38	62.8	NINCDS	P.L. Kornblith	?
CNS:U251	Central nervous system	75	M	NA	no	Glioblastoma,ud	NA	2n+, Hyperdiploid (47-57)	MT	-19	23.8	University of Uppsala, Sweden	?	J Neuropathol Exp Neurol 40: 410-427, 1981
CO:COLO205	Colon	70	M	NA	yes	Adenocarcinoma	Ascites	3n, Triploid (69)	MT	7	23.8	Denver Medical Hospital	G.E. Moore	Can Res. 38: 1345-1355, 1978
CO:HCC_2998	Colon	NA	NA	NA	yes	carcinoma	NA	2n+/-, Near-diploid 46+/- (35-57)	MT	-5	31.5	MD Anderson Hospital and Tumor Institute	?	?
CO:HCT_116	Colon	NA	M	NA	yes	carcinoma-vpd	NA	2n-, Hypodiploid (35-45)	?	26	17.4	Baylor College	?	Can Res 41: 1761-1756, 1981
CO:HCT_15	Colon	NA	NA	None	yes	Adenocarcinoma p/md	NA	2n+/-, Near-diploid 46+/- (35-57)	?	414	20.6	ATCC	ATCC (D.L. Dexter, Roger Williams General Hospital)	Can Res 39: 1020-1025, 1979
CO:HT29	Colon	44	F	None	yes	Adenocarcinoma-md	Primary	3n+/-, Near-triploid 69+/- (58-80)	MT	15	19.5	Memorial Sloan Kettering Cancer Center	J. Fogh	Human Tumor Cells in vitro: 115-159, 1975
CO:KM12	Colon	NA	NA	None	yes	Adenocarcinome-pd	NA	2n+/-, Near-diploid 46+/- (35-57)	MT	-19	23.7	MD Anderson Hospital and Tumor Institute	I.J. Fidler, Univ of Texas M.D. Anderson Hospital and Tumor Institute	Can Res 48: 1943-1948, 1988
CO:SW_620	Colon	51	M	NA	yes	Carcinoma-ud	NA	2n+/-, Near-diploid 46+/- (35-57)	MT	31	20.4	Scott White Clinic	A. Leibovitz	Can Res 1976 Dec;36(12):4562-9
LE:CCRF_CEM	Leukemia	4	F	Rad/Mtx/Ctx	no	ALL	NA	2n+/-, Near-diploid 46+/- (35-57)	MT	35	26.7	Children's Cancer research Foudation	G.E. Foley	Cancer 18: 522-529, 1965
LE:HL_60	Leukemia	36	F	None	no	Pro myelocytic leukemia	PBL	2n+/-, Near-diploid 46+/- (35-57)	MT	-11	28.6	NCI	R.C. Gallo	Blood 54(3):713-33, 1979
LE:K_562	Leukemia	53	F	Bisulfan/PiBr	no	CML	Pleural effusion	3n-, Hypotriploid (58-68)	MT	-1	19.6	University of Tennesse	H.T. Holden	Blood 45: 321-334, 1975
LE:MOLT_4	Leukemia	19	M	VB/6MP/Pred	no	ALL (cells were taken when patient was in relapse)	PB	4n, Tetraploid (92)	WT	10	27.9	Roswell Park Memorial Institute	J. Minowada	J. Natl. Cancer Inst. 49: 891-895, 1972
LE:RPMI_8226	Leukemia	61	M	None	no	Myeloma	PB	3n-, Hypotriploid (58-68)	WT	-3	33.5	?	G.E. Moore	Proc Soc Exp Biol Med 125: 1246-1250, 1967
LE:SR	Leukemia	11	M	None	no	Lymphoma	NA	2n+/-, Near-diploid 46+/- (35-57)	?	4	28.7	Program Resources, Inc.	W.J. Urba, Program Resources, Inc.	?
ME:LOXIMVI (h)	Melanoma	58	M	None	no	Malignant amelanotic melanoma	NA	3n+/-, Near-triploid 69+/- (58-80)	WT	12	20.5	Norsk Hydro's Institut, Norway	?	Int J Cancer 41: 442-449, 1988
ME:MALME_3M	Melanoma	43	M	None	no	Malignant melanotic melanoma	Metastasis	4n+/-, Near-tetraploid 92+/- (81-103)	WT	22	46.2	Memorial Sloan Kettering Cancer Center	J. Fogh	J. Natl. Cancer Inst. 59: 221-226, 1977
ME:M14	Melanoma	NA	NA	NA	no	Melanotic melanoma	NA	3n+/-, Near-triploid 69+/- (58-80)	MT	14	26.3	John Wayne Cancer Clinic, UCLA School of Medicine	D.H. Kern, John Wayne Cancer Clinic, UCLA School of Medicine	Cancer Res 48: 578-582, 1988
ME:SK_MEL_2	Melanoma	60	M	None	no	Malignant melanotic melanoma	Metastasis	4n-, Hypotetraploid (81-91)	WT	14	45.5	Memorial Sloan Kettering Cancer Center	G. Trempe; L.J. Old	Human Tumor Cells in vitro, pp 115-159, 1975
ME:SK_MEL_28	Melanoma	51	M	None	no	Malignant melanotic melanoma	NA	4n-, Hypotetraploid (81-91)	MT	11	35.1	Memorial Sloan Kettering Cancer Center	T. Takahashi	PNAS 73: 3278-3282, 1976
ME:SK_MEL_5	Melanoma	24	F	None	no	Malignant melanotic melanoma	Metastasis	4n+, Hypertetraploid (93-103)	WT	12	25.2	Memorial Sloan Kettering Cancer Center	T. Takahashi	PNAS, 73: 3278-3282, 1976
ME:UACC_257	Melanoma	NA	NA	NA	no	Melanotic melanoma	NA	3n+, Hypertriploid (70-80)	WT	26	38.5	University of Arizona	A. Leibovitz, UACC	?
ME:UACC_62	Melanoma	NA	NA	NA	no	Melanotic melanoma	NA	3n+/-, Near-triploid 69+/- (58-80)	WT	8	31.3	University of Arizona	A. Leibovitz, UACC	?
ME:MDA_MB_435 (i)	Melanoma	31	F	NA	no	Ductal carcinoma- mammary gland; breast; duct; metastatic site: pleural effusion;	Pleural effusion	2n+, Hyperdiploid (47-57)	MT	20	25.8	?	R. Cailleau	Cancer Res 40:3118-3129,1980
ME:MDA_N (j)	Melanoma	31	F	NA	no	Ductal carcinoma- mammary gland; breast; duct; metastatic site: pleural effusion;	Pleural effusion	NA	MT	12	22.5	?	?	?
LC:A549	Non-Small Cell Lung	58	M	NA	yes	Adenocarcinoma-p/md	NA	3n+/-, Near-triploid 69+/- (58-80)	WT	10	22.9	NCI	Giard DJ	J Natl Cancer Inst. 51(5):1417-23, 1973
LC:EKVX	Non-Small Cell Lung	NA	M	NA	yes	Adenocarcinoma-md	NA	3n+/-, Near-triploid 69+/- (58-80)	MT	-9	43.6	Norsk Hydro's Institut, Norway	?	?
LC:HOP_62	Non-Small Cell Lung	60	F	None	yes	adenocarcinoma-ud	NA	4n+, Hypertetraploid (93-103)	MT	61	39	Johns Hopkins University	M.Liu	?
LC:HOP_92	Non-Small Cell Lung	62	M	None	yes	Large cell-ud	NA	4n+/-, Near-tetraploid 92+/- (81-103)	MT	-4	79.5	Johns Hopkins University	M.Liu	?
LC:NCI_H226	Non-Small Cell Lung	NA	M	None (non smoker)	yes	Squamous cell carcinoma-vpd	NA	3n, Triploid (69)	MT	7	61	NCI	J.D. Minna; A.F. Gazdar	Cancer Res. 40: 3502-3507, 1980
LC:NCI_H23	Non-Small Cell Lung	NA	M	None	yes	Adenocarcinoma-ud	NA	2n+, Hyperdiploid (47-57)	MT	-2	33.4	NCI	J.D. Minna; A.F. Gazdar	Cancer Res. 40: 3502-3507, 1980
LC:NCI_H322M	Non-Small Cell Lung	52	M	None	yes	Small cell Bronchioalveolar Carcinoma	NA	2n+/-, Near-diploid 46+/- (35-57)	MT	-10	35.3	NCI	?	?
LC:NCI_H460	Non-Small Cell Lung	NA	M	NA	yes	Large Cell Carcinoma-ud	Pleural effusion	2n+/-, Near-diploid 46+/- (35-57)	WT	25	17.8	NCI	J.D. Minna; A.F. Gazdar	Science 246: 491-494, 1989
LC:NCI_H522	Non-Small Cell Lung	NA	M	None	yes	Adenocarcinoma-vpd	NA	2n+/-, Near-diploid 46+/- (35-57)	MT	16	38.2	NCI	?	Can Res 45: 2913-2923, 1985
OV:IGROV1	Ovarian	47	F	Rad	yes	Cystoadenocarcinoma-pd	NA	4n+/-, Near-tetraploid 92+/- (81-103)	MT	20	31	Institute Gustave Roussy, France	?	Can Res 45: 4970-4979,1985
OV:OVCAR_3	Ovarian	60	F	CyPh/CsPt/Adr	yes	Adenocarcinoma-md	Ascites	3n+/-, Near-triploid 69+/- (58-80)	MT	-12	34.7	NCI	T.C. Hamilton	Sem Ocol 11: 285-298, 1984
OV:OVCAR_4	Ovarian	42	F	CyPh/CsPt/Adr	yes	Adenocarcinoma-md	NA	3n+/-, Near-triploid 69+/- (58-80)	WT	-4	41.4	NCI	T.C. Hamilton	Sem Ocol 11: 285-298, 1984
OV:OVCAR_5	Ovarian	67	F	None	yes	Adenocarcinoma-wd	NA	2n+, Hyperdiploid (47-57)	MT	13	48.8	NCI	R. Ozols	Sem Ocol 11: 285-298, 1985
OV:OVCAR_8	Ovarian	64	F	Ctx/Adr/CsPt/CyPh	yes	Carcinoma-ud	NA	2n+, Hyperdiploid (47-57)	MT	7	26.1	NCI	T.C. Hamilton	?
OV:SK_OV_3	Ovarian	64	F	Thiotepa	yes	Adenocarcinoma-vpd	Ascites	4n+/-, Near-tetraploid 92+/- (81-103)	?	15	48.7	Memorial Sloan Kettering Cancer Center	?	Human Tumor Cells in vitro, pp. 115-159, 1975
OV:NCI_ADR_RES (k)	Ovarian	NA	F	NA	yes	Adenocarinoma	NA	2n+/-, Near-diploid 46+/- (35-57)	MT	352	34	NCI	K.Cowan, NCI	Cancer Res., 46:4087-4090,1986
PR:PC_3	Prostate	62	M	NA	yes	Adenocarcinoma- prostate; metastatic site: bone;	NA	4n, Tetraploid (92)	MT	11	27.1	Pasadena Center for Medical Research	M.E. Kaighn	Invest Urol 1979 Jul;17(1):16-23
PR:DU_145	Prostate	69	M	Androgen independent and unresposive to hormone therapy	yes	prostate; metastatic site: brain; carcinoma (patient with metastatic carcinoma of the prostate and a 3 year history of lymphocytic leukemia.)	Metastasis	3n+/-, Near-triploid 69+/- (58-80)	?	4	32.3	Washington University School of Medicine, Saint Louis, MO	K.R. Stone	Int J Cancer 21: 274-281,1978
RE:786_0	Renal	58	M	None	yes	Adenocarcinoma	NA	4n+/-, Near-tetraploid 92+/- (81-103)	MT	-44	22.4	?	R.D.Williams, Univ. of Iowa	In Vitro 14: 779-786, 1978
RE:A498	Renal	52	F	NA	yes	Adenocarcinoma	NA	3n, Triploid (69)	WT	78	66.8	NCI	?	JNCI 51: 1417-1423,1973
RE:ACHN	Renal	22	M	Rad/VB/CCNU/Mto/Pred	yes	Renal cell carcinoma-p/md	NA	2n+/-, Near-diploid 46+/- (35-57)	WT	120	27.5	Southern Research Inst. (T.F. Hogan, Middleton memorial VA hospital)	S.M.Schmid	Cancer Res 42: 4948-4953, 1982
RE:CAKI_1	Renal	49	M	Rad/HU/5FU/Mtx/Ctx	yes	Clear cell carcinoma	Metastasis	3n, Triploid (69)	WT	171	39	Memorial Sloan Kettering Cancer Center	J. Fogh	Human Tumor cells in vitro, pp 115-159, 1975
RE:RXF_393	Renal	54	M	None	yes	hypernephroma-pd	NA	3n+/-, Near-triploid 69+/- (58-80)	MT	42	62.9	MD Anderson Hospital and Tumor Institute	NCI/DCT/DTP	Contrib oncol 42, 1992 
RE:SN12C	Renal	43	M	None	yes	Renal cell carcinoma-pd	NA	3n, Triploid (69)	MT	-86	29.5	MD Anderson Hospital and Tumor Institute	.J.Fidler	Cancer Res 46: 4109-4115, 1986
RE:TK_10	Renal	43	M	None	yes	Renal Spindle cell carcinoma	NA	4n, Tetraploid (92)	MT	-4	51.3	?	R.V.Clayman, Washington Univ.School of Medicine	Cancer Res 46: 3856-3862, 1987
RE:UO_31	Renal	NA	F	None	yes	Renal cell carcinoma-vpd	NA	2n+/-, Near-diploid 46+/- (35-57)	WT	59	41.7	NCI	W.M.Linehan	?
																												
														
Footnotes
(a) Information from Stinson, et al., (Anticancer Res. 1992 Jul-Aug;12(4):1035-53), DTP, ATCC, and other sources.														
(b) Prior_Treatment: BCNU=Bis(chlorethyl)nitrosourea;CCNU=chloroethylecyclohexylnitrosourea; CyPh=cyclophosphamide;CsPt=cisplatin;Ctx=cytoxan;5FU=5-fluorouracil; Hu=hydroxyurea;Mto=mitoxantrone;Pred=prednisone;VB=vinblastine;6MP=6-mercaptopurine; Rad=radiation;Mtx=methotrexate;PiBr=piprobromine;Adr=adriamycin.														
(c) "UD" in the histology column is undifferentiated.														
(d) ploidy information from the NCBI SKY/M-FISH and CGH Database (Roschke AV, Tonon G, et al, Cancer Res. 63 : 8634-8647, 2003)														
(e) p53 status as determined by yeast growth functional assay: PM O'Conner, et al. (Cancer Res. 1997 Oct 1;57(19):4285-300).														
(f) MDR Function: from DTP site (Lee JS etal., Mol Pharmacol. 1994 Oct;46(4):627-38)														
(g) Doubling times described at DPT.														
(h) ME:LOXIMVI is amelanotic.
(i) ME:MDA_MB435 was apparently derived from the pleural effusion of a patient with breast cancer, and it has been reported to express some proteins characteristic of
breast origin.  However, its molecular profiles in all of our databases (transcript expression, protein expression, drug sensitivity, etc.) are absolutely characteristic
of melanotic melanoma (see, e.g., Scherf, et al., Nat. Genet. 24:236 (2000); Ross, et al., ibid, 24:227 (2000)).
(j) ME:MDA_N was derived from ME:MDA_MB_435 by transfection with a plasmid designed to express erbB2. ME:MDA_N and ME:MDA_MB_435 are very similar 
under non selective conditions.
(k) OV:NCI_ADR-RES (called NCI-ADR-RES in DTP tabulations) was derived from OVCAR8 by culturing with Adriamycin and is classically multi-drug resistant. It was originally 
called, MCF7_ADR-RES, then the agnostic NCI_ADR-RES, but our SKY (Roschke, et al., Cancer Res. 63:8634 (2003)) and CGH (Bussey, et al., Mol. Ca. Ther. 5:853 (2006))
studies clearly showed its derivation from OVCAR8.